OMB's Grogan Talks Drug Pricing And Taking On 'Sacred Cows'
Concerns with promoting competition and reducing consumers' 'pain in the pocketbook' are key tenets of the Trump Administration's approach to lowering prescription drug pricing, Grogan says.
You may also be interested in...
COVID-19 And The Future Of Rx Pricing Policy: An Interview With White House Advisor Grogan
White House Domestic Policy Council Director Joe Grogan is departing at the end of May. In an interview, he talked about lessons (so far) from the COVID-19 response and the future of drug pricing policy against the backdrop of the pandemic.
The Ups and Downs Of US Drug Pricing Policy
If 2017 was the year of talk (tweets) on prescription drug pricing policy, 2018 is shaping up to be the year of action.
HHS Nominee Azar: Great News For Industry But ACA Reform Will Be Priority
Insurance practices are a big driver of drug pricing problems, according to Azar, a former Lilly exec who spent six years at HHS under George W. Bush, providing him valuable experience in department operations.